Pretreatment Neutrophil-to-Lymphocyte Ratio: A Predictor of Advanced Prostate Cancer and Biochemical Recurrence in Patients Receiving Radical Prostatectomy

The pretreatment neutrophil-to-lymphocyte ratio (NLR) is reportedly associated with the clinical outcomes of many cancers. However, it has not been widely investigated whether the pretreatment NLR is associated with the pathological characteristics of prostate cancer (PCa) and biochemical recurrence...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Gui-Ming, Zhu, Yao, Ma, Xiao-Cheng, Qin, Xiao-Jian, Wan, Fang-Ning, Dai, Bo, Sun, Li-Jiang, Ye, Ding-Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4616804/
https://www.ncbi.nlm.nih.gov/pubmed/26469891
http://dx.doi.org/10.1097/MD.0000000000001473
_version_ 1782396716788482048
author Zhang, Gui-Ming
Zhu, Yao
Ma, Xiao-Cheng
Qin, Xiao-Jian
Wan, Fang-Ning
Dai, Bo
Sun, Li-Jiang
Ye, Ding-Wei
author_facet Zhang, Gui-Ming
Zhu, Yao
Ma, Xiao-Cheng
Qin, Xiao-Jian
Wan, Fang-Ning
Dai, Bo
Sun, Li-Jiang
Ye, Ding-Wei
author_sort Zhang, Gui-Ming
collection PubMed
description The pretreatment neutrophil-to-lymphocyte ratio (NLR) is reportedly associated with the clinical outcomes of many cancers. However, it has not been widely investigated whether the pretreatment NLR is associated with the pathological characteristics of prostate cancer (PCa) and biochemical recurrence in PCa patients receiving radical prostatectomy (RP). In this cohort study, a total of 1688 PCa patients who had undergone RP were analyzed retrospectively, and a subset of 237 of these patients were evaluated to determine the relationship between pretreatment NLR and biochemical recurrence. Patients were divided into a high-NLR group (NLR ≥2.36) and a low-NLR group (NLR < 2.36) according to the pretreatment NLR. The association between the pretreatment NLR and pathological stage and lymph node involvement was evaluated using logistic regression analysis. Time of biochemical recurrence was determined using the Kaplan–Meier method. Cox's proportional hazard regression model was used to compare the time of biochemical recurrence between the groups. As compared with patients in the low-NLR group, those in the high-NLR group had an increased risk of pT3–4 disease (odds ratio (OR), 1.883; 95% confidence interval (CI), 1.419–2.500; P < 0.001), and a 1.7-fold increased risk of lymph node involvement (OR, 1.685; 95% CI, 1.101–2.579; P = 0.016). For the subset of 237 patients, those with a high NLR showed a significantly shorter median biochemical recurrence-free survival time (51.9 months) than those with a low NLR (76.5 months; log-rank test, P = 0.019). However, multivariate analysis indicated that the NLR was not an independent predictor of biochemical recurrence (hazard ratio, 1.388; 95% CI, 0.909–2.118; P = 0.129). Our findings suggest that the pretreatment NLR may be associated with pathological stage and lymph node involvement in PCa patients receiving RP, and that PCa patients with a high NLR may have a higher rate of biochemical recurrence following RP than those with a low NLR.
format Online
Article
Text
id pubmed-4616804
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-46168042015-10-27 Pretreatment Neutrophil-to-Lymphocyte Ratio: A Predictor of Advanced Prostate Cancer and Biochemical Recurrence in Patients Receiving Radical Prostatectomy Zhang, Gui-Ming Zhu, Yao Ma, Xiao-Cheng Qin, Xiao-Jian Wan, Fang-Ning Dai, Bo Sun, Li-Jiang Ye, Ding-Wei Medicine (Baltimore) 7300 The pretreatment neutrophil-to-lymphocyte ratio (NLR) is reportedly associated with the clinical outcomes of many cancers. However, it has not been widely investigated whether the pretreatment NLR is associated with the pathological characteristics of prostate cancer (PCa) and biochemical recurrence in PCa patients receiving radical prostatectomy (RP). In this cohort study, a total of 1688 PCa patients who had undergone RP were analyzed retrospectively, and a subset of 237 of these patients were evaluated to determine the relationship between pretreatment NLR and biochemical recurrence. Patients were divided into a high-NLR group (NLR ≥2.36) and a low-NLR group (NLR < 2.36) according to the pretreatment NLR. The association between the pretreatment NLR and pathological stage and lymph node involvement was evaluated using logistic regression analysis. Time of biochemical recurrence was determined using the Kaplan–Meier method. Cox's proportional hazard regression model was used to compare the time of biochemical recurrence between the groups. As compared with patients in the low-NLR group, those in the high-NLR group had an increased risk of pT3–4 disease (odds ratio (OR), 1.883; 95% confidence interval (CI), 1.419–2.500; P < 0.001), and a 1.7-fold increased risk of lymph node involvement (OR, 1.685; 95% CI, 1.101–2.579; P = 0.016). For the subset of 237 patients, those with a high NLR showed a significantly shorter median biochemical recurrence-free survival time (51.9 months) than those with a low NLR (76.5 months; log-rank test, P = 0.019). However, multivariate analysis indicated that the NLR was not an independent predictor of biochemical recurrence (hazard ratio, 1.388; 95% CI, 0.909–2.118; P = 0.129). Our findings suggest that the pretreatment NLR may be associated with pathological stage and lymph node involvement in PCa patients receiving RP, and that PCa patients with a high NLR may have a higher rate of biochemical recurrence following RP than those with a low NLR. Wolters Kluwer Health 2015-10-16 /pmc/articles/PMC4616804/ /pubmed/26469891 http://dx.doi.org/10.1097/MD.0000000000001473 Text en Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0
spellingShingle 7300
Zhang, Gui-Ming
Zhu, Yao
Ma, Xiao-Cheng
Qin, Xiao-Jian
Wan, Fang-Ning
Dai, Bo
Sun, Li-Jiang
Ye, Ding-Wei
Pretreatment Neutrophil-to-Lymphocyte Ratio: A Predictor of Advanced Prostate Cancer and Biochemical Recurrence in Patients Receiving Radical Prostatectomy
title Pretreatment Neutrophil-to-Lymphocyte Ratio: A Predictor of Advanced Prostate Cancer and Biochemical Recurrence in Patients Receiving Radical Prostatectomy
title_full Pretreatment Neutrophil-to-Lymphocyte Ratio: A Predictor of Advanced Prostate Cancer and Biochemical Recurrence in Patients Receiving Radical Prostatectomy
title_fullStr Pretreatment Neutrophil-to-Lymphocyte Ratio: A Predictor of Advanced Prostate Cancer and Biochemical Recurrence in Patients Receiving Radical Prostatectomy
title_full_unstemmed Pretreatment Neutrophil-to-Lymphocyte Ratio: A Predictor of Advanced Prostate Cancer and Biochemical Recurrence in Patients Receiving Radical Prostatectomy
title_short Pretreatment Neutrophil-to-Lymphocyte Ratio: A Predictor of Advanced Prostate Cancer and Biochemical Recurrence in Patients Receiving Radical Prostatectomy
title_sort pretreatment neutrophil-to-lymphocyte ratio: a predictor of advanced prostate cancer and biochemical recurrence in patients receiving radical prostatectomy
topic 7300
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4616804/
https://www.ncbi.nlm.nih.gov/pubmed/26469891
http://dx.doi.org/10.1097/MD.0000000000001473
work_keys_str_mv AT zhangguiming pretreatmentneutrophiltolymphocyteratioapredictorofadvancedprostatecancerandbiochemicalrecurrenceinpatientsreceivingradicalprostatectomy
AT zhuyao pretreatmentneutrophiltolymphocyteratioapredictorofadvancedprostatecancerandbiochemicalrecurrenceinpatientsreceivingradicalprostatectomy
AT maxiaocheng pretreatmentneutrophiltolymphocyteratioapredictorofadvancedprostatecancerandbiochemicalrecurrenceinpatientsreceivingradicalprostatectomy
AT qinxiaojian pretreatmentneutrophiltolymphocyteratioapredictorofadvancedprostatecancerandbiochemicalrecurrenceinpatientsreceivingradicalprostatectomy
AT wanfangning pretreatmentneutrophiltolymphocyteratioapredictorofadvancedprostatecancerandbiochemicalrecurrenceinpatientsreceivingradicalprostatectomy
AT daibo pretreatmentneutrophiltolymphocyteratioapredictorofadvancedprostatecancerandbiochemicalrecurrenceinpatientsreceivingradicalprostatectomy
AT sunlijiang pretreatmentneutrophiltolymphocyteratioapredictorofadvancedprostatecancerandbiochemicalrecurrenceinpatientsreceivingradicalprostatectomy
AT yedingwei pretreatmentneutrophiltolymphocyteratioapredictorofadvancedprostatecancerandbiochemicalrecurrenceinpatientsreceivingradicalprostatectomy